Theravance Biopharma Company Profile (NASDAQ:TBPH)

About Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma logoTheravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TBPH
  • CUSIP: N/A
  • Web: www.theravance.com
Capitalization:
  • Market Cap: $1.79 billion
  • Outstanding Shares: 53,361,000
Average Prices:
  • 50 Day Moving Avg: $39.02
  • 200 Day Moving Avg: $35.71
  • 52 Week Range: $23.80 - $43.44
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.41
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $33.33 million
  • Price / Sales: 53.60
  • Book Value: $5.52 per share
  • Price / Book: 6.07
Profitability:
  • EBIDTA: ($194,150,000.00)
  • Net Margins: -641.67%
  • Return on Equity: -67.69%
  • Return on Assets: -43.68%
Debt:
  • Debt-to-Equity Ratio: 0.76%
  • Current Ratio: 8.61%
  • Quick Ratio: 8.34%
Misc:
  • Average Volume: 221,057 shs.
  • Beta: 2.34
  • Short Ratio: 29.09
 
Frequently Asked Questions for Theravance Biopharma (NASDAQ:TBPH)

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($1.27) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.14) by $0.13. The company earned $3.09 million during the quarter, compared to analyst estimates of $5.07 million. Theravance Biopharma had a negative net margin of 641.67% and a negative return on equity of 67.69%. View Theravance Biopharma's Earnings History.

When will Theravance Biopharma make its next earnings announcement?

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Theravance Biopharma.

Where is Theravance Biopharma's stock going? Where will Theravance Biopharma's stock price be in 2017?

8 analysts have issued 1-year target prices for Theravance Biopharma's shares. Their forecasts range from $24.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $42.00 in the next year. View Analyst Ratings for Theravance Biopharma.

What are analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:

  • 1. Needham & Company LLC analysts commented, "Theravance mgmt hosted a 4Q16 conference call late yesterday to provide a corporate update. We note several expected milestones in 2017. Results from Phase 1b TD-1473 trial in Ulcerative Colitis in mid-2017 are of particular interest, given size of market and differentiated mechanism (GI-restricted JAK inhibitor). We are favorably inclined. A second distinct JAK inhibitor, TD-3504 (GIrestricted tofacitinib prodrug), is expected to enter Phase 1 testing in 1H17 as a backup option. Other events include NDA submission for revefenacin in Chronic Obstructive Pulmonary Disease w/ collaborator Mylan, potential FDA approval of Closed Triple by collaborator GSK, as well as results from Phase 2 trials of TD-9855 in Neurogenic Orthostatic Hypotension and velusetrag in Gastroparesis." (2/28/2017)
  • 2. According to Zacks Investment Research, "Theravance’s sole marketed product, Vibativ, continues to perform well, contributing meaningfully to the top line at the company. However, Vibativ witnessed a sequential decline due to seasonality and trends in surgical admissions. Nevertheless, the company’s efforts on the commercialization of Vibativ are encouraging. We are also positive on its efforts to expand the drug’s label, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Theravance’s progress with the rest of the pipeline is also impressive. Shares of the company have significantly outperformed the Medical-Drugs industry in 2016. Moreover, estimates have gone up ahead of the release of the company’s fourth-quarter 2016 results. However, Theravance’s heavy dependence on Vibativ for growth is concerning." (1/3/2017)
  • 3. Leerink Swann analysts commented, "We reiterate our Outperform rating for Theravance’s stock. Stronger than expected Vibativ sales driven by a combination of new indication and expansion of dedicated sales force. Sales of Vibativ increased by 62% QoQ and 152% YoY apparently driven by the expansion of the sales force from 6 to 50 reps in 4Q15 and the opportunity presented by the expanded label. Mgmt believes the growth in revenue will continue driven by the expansion of accounts and positive physician perception in using Vibativ in difficult to treat patients. Several catalysts in next 12 months could potentially add additional value to the company. As highlighted in our earlier note [LINK], our sum of the parts analysis identified potential 20% and 70% upside by end of 2016 and 2017, respectively." (8/9/2016)

Who are some of Theravance Biopharma's key competitors?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:

  • Rick E. Winningham, Chairman of the Board, Chief Executive Officer
  • Renee D. Gala, Senior Vice President, Chief Financial Officer, Treasurer
  • Bradford J. Shafer Esq. J.D., Executive Vice President, General Counsel, Secretary
  • Brett K. Haumann M.D., Senior Vice President - Clinical Development and Chief Medical Officer
  • Sharathchandra S. Hegde, Senior Vice President, Research
  • Frank Pasqualone, Senior Vice President and Chief Commercial Operations Officer
  • Kenneth R. Pitzer, Senior Vice President - Product Strategy and Commercial Planning
  • Philip D. Worboys Ph.D., Senior Vice President, Translational Science
  • William D. Young, Lead Independent Director
  • Eran Broshy, Independent Director

Who owns Theravance Biopharma stock?

Theravance Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.04%), Public Employees Retirement Association of Colorado (0.02%) and Aperio Group LLC (0.01%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.

Who bought Theravance Biopharma stock? Who is buying Theravance Biopharma stock?

Theravance Biopharma's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Aperio Group LLC. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Junning Lee, Plc Glaxosmithkline, Renee D Gala and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.

How do I buy Theravance Biopharma stock?

Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of Theravance Biopharma stock can currently be purchased for approximately $33.48.


MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Theravance Biopharma (NASDAQ:TBPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $42.00 (25.45% upside)

Analysts' Ratings History for Theravance Biopharma (NASDAQ:TBPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/19/2017Cantor FitzgeraldSet Price TargetBuy$55.00HighView Rating Details
5/10/2017Leerink SwannSet Price TargetBuy$47.00LowView Rating Details
5/11/2017Needham & Company LLCBoost Price TargetBuy -> Buy$40.00 -> $45.00LowView Rating Details
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$42.00MediumView Rating Details
10/12/2016Robert W. BairdDowngradeNeutral -> Underperform$19.00 -> $24.00N/AView Rating Details
9/19/2016GuggenheimReiterated RatingPositive$40.00N/AView Rating Details
8/29/2016Evercore ISIInitiated CoverageBuy$41.00N/AView Rating Details
8/3/2016Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Theravance Biopharma (NASDAQ:TBPH)
Earnings by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Earnings History by Quarter for Theravance Biopharma (NASDAQ TBPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017($1.16)N/AView Earnings Details
5/9/20173/31/2017($1.14)($1.27)$5.07 million$3.09 millionViewListenView Earnings Details
2/27/2017Q416($1.05)($1.36)$5.00 million$5.69 millionViewListenView Earnings Details
8/8/2016Q216($1.05)($1.06)$6.19 million$5.47 millionViewN/AView Earnings Details
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details
11/6/2014Q3 14($1.85)($1.72)$1.08 million$6.34 millionViewN/AView Earnings Details
8/13/2014($0.56)($1.83)$1.01 million$2.97 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Theravance Biopharma (NASDAQ:TBPH)
2017 EPS Consensus Estimate: ($4.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.04)($1.04)($1.04)
Q2 20171($1.07)($1.07)($1.07)
Q3 20171($1.09)($1.09)($1.09)
Q4 20171($1.10)($1.10)($1.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Theravance Biopharma (NASDAQ:TBPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Theravance Biopharma (NASDAQ:TBPH)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 84.30%
Insider Trades by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Insider Trades by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/7/2017Brett K HaumannSVPSell424$30.80$13,059.20View SEC Filing  
3/6/2017Brett K HaumannSVPSell13,576$31.52$427,915.52View SEC Filing  
8/25/2016Brett K HaumannSVPSell4,491$27.99$125,703.09View SEC Filing  
8/22/2016Bradford J ShaferEVPSell49,122$27.46$1,348,890.12View SEC Filing  
8/19/2016Brett K HaumannSVPSell9,509$27.97$265,966.73View SEC Filing  
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Theravance Biopharma (NASDAQ:TBPH)
Latest Headlines for Theravance Biopharma (NASDAQ:TBPH)
Source:
DateHeadline
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Cut to Sell at BidaskClub
www.americanbankingnews.com - July 27 at 8:30 PM
finance.yahoo.com logoETFs with exposure to Theravance Biopharma, Inc. : July 25, 2017
finance.yahoo.com - July 26 at 8:36 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 10:54 AM
americanbankingnews.com logoTheravance Biopharma Inc (NASDAQ:TBPH) PT Set at $55.00 by Cantor Fitzgerald
www.americanbankingnews.com - July 23 at 4:20 PM
americanbankingnews.com logo Brokerages Anticipate Theravance Biopharma, Inc. (TBPH) Will Announce Quarterly Sales of $4.06 Million
www.americanbankingnews.com - July 22 at 7:32 AM
americanbankingnews.com logoZacks: Analysts Anticipate Theravance Biopharma, Inc. (NASDAQ:TBPH) Will Post Earnings of -$1.13 Per Share
www.americanbankingnews.com - July 20 at 10:15 PM
finance.yahoo.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : July 17, 2017
finance.yahoo.com - July 18 at 8:49 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Downgraded by BidaskClub
www.americanbankingnews.com - July 16 at 9:32 PM
finance.yahoo.com logoETFs with exposure to Theravance Biopharma, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 9:17 AM
americanbankingnews.com logoTheravance Biopharma, Inc. to Post FY2017 Earnings of ($4.46) Per Share, Cantor Fitzgerald Forecasts (TBPH)
www.americanbankingnews.com - July 6 at 8:45 AM
americanbankingnews.com logoZacks: Analysts Anticipate Theravance Biopharma, Inc. (TBPH) Will Post Quarterly Sales of $4.06 Million
www.americanbankingnews.com - June 28 at 10:33 AM
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 27 at 9:26 AM
americanbankingnews.com logoZacks: Analysts Anticipate Theravance Biopharma, Inc. (TBPH) to Post -$1.13 EPS
www.americanbankingnews.com - June 26 at 8:40 PM
americanbankingnews.com logoTheravance Biopharma, Inc. (TBPH) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - June 24 at 3:38 PM
americanbankingnews.com logoCantor Fitzgerald Initiates Coverage on Theravance Biopharma, Inc. (TBPH)
www.americanbankingnews.com - June 16 at 10:06 AM
finance.yahoo.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : June 15, 2017
finance.yahoo.com - June 15 at 4:37 PM
finance.yahoo.com logoTheravance (TBPH) Down 5.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 13 at 9:36 AM
prnewswire.com logoNew Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin ...
www.prnewswire.com - June 7 at 10:00 AM
finance.yahoo.com logoETFs with exposure to Theravance Biopharma, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 6:42 PM
finance.yahoo.com logoNew Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017
finance.yahoo.com - June 5 at 1:41 PM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - June 3 at 12:57 AM
finance.yahoo.com logoTheravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 3:17 PM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $4.06 Million
www.americanbankingnews.com - June 2 at 1:12 PM
americanbankingnews.com logoZacks: Analysts Expect Theravance Biopharma Inc (TBPH) Will Post Earnings of -$1.16 Per Share
www.americanbankingnews.com - May 31 at 4:44 PM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 31 at 10:02 AM
finance.yahoo.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : TBPH-US : May 29, 2017
finance.yahoo.com - May 29 at 12:12 PM
finance.yahoo.com logoTheravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : May 19, 2017
finance.yahoo.com - May 19 at 6:01 PM
finance.yahoo.com logoTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : May 18, 2017
finance.yahoo.com - May 18 at 12:47 PM
americanbankingnews.com logoShort Interest in Theravance Biopharma Inc (TBPH) Rises By 12.6%
www.americanbankingnews.com - May 16 at 7:20 AM
americanbankingnews.com logoNeedham & Company LLC Boosts Theravance Biopharma Inc (TBPH) Price Target to $45.00
www.americanbankingnews.com - May 14 at 12:32 AM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Given a $47.00 Price Target at Leerink Swann
www.americanbankingnews.com - May 13 at 5:14 PM
americanbankingnews.com logoLeerink Swann Analysts Decrease Earnings Estimates for Theravance Biopharma Inc (TBPH)
www.americanbankingnews.com - May 12 at 10:58 AM
finance.yahoo.com logoEdited Transcript of TBPH earnings conference call or presentation 9-May-17 9:00pm GMT
finance.yahoo.com - May 11 at 1:55 AM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - May 10 at 6:20 PM
finance.yahoo.com logoInvestor Network: Theravance Biopharma Inc to Host Earnings Call
finance.yahoo.com - May 9 at 7:37 PM
finance.yahoo.com logoTheravance Biopharma, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 9 at 7:37 PM
finance.yahoo.com logoTheravance Bio reports 1Q loss
finance.yahoo.com - May 9 at 7:37 PM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $5.07 Million
www.americanbankingnews.com - May 7 at 8:06 AM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) to Release Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:40 AM
americanbankingnews.com logoTheravance Biopharma Inc (TBPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 5 at 9:08 PM
americanbankingnews.com logo Brokerages Anticipate Theravance Biopharma Inc (TBPH) to Post -$1.14 EPS
www.americanbankingnews.com - May 5 at 4:19 PM
americanbankingnews.com logoFavorable Media Coverage Somewhat Likely to Impact Theravance Biopharma (TBPH) Stock Price
www.americanbankingnews.com - May 3 at 9:16 PM
finance.yahoo.com logoTheravance Biopharma to Report First Quarter 2017 Financial Results on May 9, 2017
finance.yahoo.com - May 2 at 9:05 AM
finance.yahoo.com logoTheravance Biopharma to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 27 at 8:58 PM
americanbankingnews.com logoTheravance Biopharma (TBPH) Getting Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 27 at 2:22 PM
finance.yahoo.com logoNew Data for VIBATIV® (telavancin) Reported in Several Presentations at ECCMID 2017
finance.yahoo.com - April 25 at 9:29 AM
streetinsider.com logoTheravance Biopharma (TBPH) Announces Positive Clinical Response Rates for Patients in TOUR™ Observational Patient Registry at ECCMID
www.streetinsider.com - April 24 at 6:31 PM
americanbankingnews.com logoPositive Press Coverage Likely to Affect Theravance Biopharma (TBPH) Stock Price
www.americanbankingnews.com - April 24 at 5:32 PM
finance.yahoo.com logoTheravance Biopharma Reports Positive Clinical Response Rates for Patients in TOUR™ Observational Patient …
finance.yahoo.com - April 24 at 10:35 AM
finance.yahoo.com logoTheravance Biopharma Reports Positive Clinical Response Rates for Patients in TOUR™ Observational Patient Registry in Several Presentations at ECCMID 2017
finance.yahoo.com - April 24 at 10:35 AM

Social

Chart

Theravance Biopharma (TBPH) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff